Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate versus placebo for fatigue in advanced cancer (MePFAC)
2017-001950-33Phase 3Unknown
- Sponsor
- UCL
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cancer-related fatigue (CRF) comparing Methylphenidate with Placebo (2 arms). Primary endpoint: Fatigue at 6 weeks (FACIT-F fatigue sub-scale). Status: unknown.
02
Drugs
methylphenidate
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on 2017-001950-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001950-33.